![Pharmaceutical Drug Pharmaceutical Industry Teva Pharmaceutical Industries Alfacalcidol Vitamin, PNG, 703x636px, Pharmaceutical Drug, Active Ingredient, Area, Pharmaceutical Drug Pharmaceutical Industry Teva Pharmaceutical Industries Alfacalcidol Vitamin, PNG, 703x636px, Pharmaceutical Drug, Active Ingredient, Area,](https://img.favpng.com/23/21/9/pharmaceutical-drug-pharmaceutical-industry-teva-pharmaceutical-industries-alfacalcidol-vitamin-png-favpng-5kQA4017s8s11n7S5ujKrgnjP.jpg)
Pharmaceutical Drug Pharmaceutical Industry Teva Pharmaceutical Industries Alfacalcidol Vitamin, PNG, 703x636px, Pharmaceutical Drug, Active Ingredient, Area,
![PDF) Alfacalcidol Reduces the Number of Fallers in a Community-Dwelling Elderly Population with a Minimum Calcium Intake of More Than 500 Mg Daily PDF) Alfacalcidol Reduces the Number of Fallers in a Community-Dwelling Elderly Population with a Minimum Calcium Intake of More Than 500 Mg Daily](https://i1.rgstatic.net/publication/8434374_Alfacalcidol_Reduces_the_Number_of_Fallers_in_a_Community-Dwelling_Elderly_Population_with_a_Minimum_Calcium_Intake_of_More_Than_500_Mg_Daily/links/57641e4d08aedbc345ecb6f6/largepreview.png)
PDF) Alfacalcidol Reduces the Number of Fallers in a Community-Dwelling Elderly Population with a Minimum Calcium Intake of More Than 500 Mg Daily
![Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min | SpringerLink Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00198-004-1671-9/MediaObjects/s00198-004-1671-9fhb2.jpg)
Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min | SpringerLink
![PDF) [Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence] PDF) [Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence]](https://i1.rgstatic.net/publication/235688078_Combination_of_alendronate_plus_alfacalcidol_in_the_treatment_of_osteoporosis_Rationale_preclinical_data_and_clinical_evidence/links/587e37e208aed3826af45521/largepreview.png)
PDF) [Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence]
![Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis | SpringerLink Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00296-003-0361-9/MediaObjects/s00296-003-0361-9fhb4.jpg)